| PD-1抑制剂治疗食管癌的临床研究新进展 |
| |
| 引用本文： | 马明全,唐鹏. PD-1抑制剂治疗食管癌的临床研究新进展[J]. 中国肿瘤临床, 2021, 48(18): 958-963. DOI: 10.12354/j.issn.1000-8179.2021.20210872 |
| |
| 作者姓名： | 马明全 唐鹏 |
| |
| 作者单位： | 天津医科大学肿瘤医院食管肿瘤科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心 （天津市 300060） |
| |
| 摘 要： | 食管癌（esophageal cancer，EC）是常见的消化系统恶性肿瘤，主要病理类型分为鳞癌（squamous cell carcinoma，SCC）和腺癌（adenocarcinoma，AC）。EC患者的传统治疗方式包括手术、化疗和放疗。然而，系统治疗仅在部分患者中疗效较好，多数患者在初始治疗后很快复发。免疫检查点抑制剂可以通过重新激活抗肿瘤免疫反应，强化对肿瘤细胞的杀伤效应来发挥作用，从而提高临床疗效。目前，程序性细胞死亡因子-1（programmed death-1，PD-1）抑制剂已成为肿瘤治疗的重要手段之一。PD-1抑制剂在EC中的研究不断增多，尽管临床试验KEYNOTE-181和ATTRACTION-03取得了较好的治疗效果，但是仍需要提高对EC免疫状况的认识，以助于制定更为有效的免疫治疗策略，从而精准选择受益患者。
|
| 关 键 词： | 食管癌 免疫检查点 PD-1 预后因子 |
| 收稿时间： | 2021-06-09 |
Research advances in immunotherapy for esophageal cancer |
| |
| Affiliation: | Department of Esophageal Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China |
| |
| Abstract: | As a common tumor of digestive system, esophageal cancer (EC) is histologically classified as either esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC). Although conventional treatment modalities for EC include surgery, chemotherapy, and radiation, not all patients respond to initial systemic treatments, with a significant proportion of patients experiencing disease recurrence after the initial treatment. Immune checkpoint inhibitors can enhance antitumor adaptive immunity by rejuvenating antitumor immune responses, thereby improving clinical outcomes. In particular, immune checkpoint inhibitors for programmed cell death-1 (PD-1) have emerged as an important treatment modality for several cancer types, with the number of clinical research on PD-1 checkpoint inhibitors for EC constantly increasing. However, despite the good preliminary clinical results of the KEYNOTE-181 and ATTRACTION-03 trials, there is an urgent need to increase awareness regarding the full scope of EC-related immunology background. Only then can we develop more effective immunotherapeutic strategies and accurately select patients who may benefit from PD-1 checkpoint inhibitors. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
